Acinetobacter baumannii:: a universal threat to public health?

被引:173
作者
Giamarellou, Helen [1 ]
Antoniadou, Anastasia [1 ]
Kanellakopoulou, Kyriaki [1 ]
机构
[1] Univ Gen Hosp ATTIKON, Dept Internal Med 4, Athens 12462, Greece
关键词
Acinetobacter baumannii; epidemiology; multiresistance; risk factors; clinical impact; therapy;
D O I
10.1016/j.ijantimicag.2008.02.013
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Acinetobacter spp. are non-fermentative, strictly aerobic, Gram-negative microorganisms with a confusing taxonomic history. The Acinetobacter baumannii-Acinetobacter calcoaceticus complex is the species most commonly isolated from clinical specimens. It is ubiquitous in nature and has been found as part of the normal skin, throat and rectal flora as well as in food and body lice. It colonises patients in Intensive Care Units and contaminates inanimate hospital surfaces and devices as well as wounds, including war injuries. Although a frequent coloniser, Acinetobacter can be the cause of severe and sometimes lethal infections, mostly of nosocomial origin, predominantly ventilator-associated pneumonia. Bacteraemic infections are rare but may evolve to septic shock. Acinetobacter also emerges as a cause of nosocomial outbreaks and is characterised by increasing antimicrobial multiresistance. Antibiotic use, especially carbapenems and third-generation cephalosporins, is recognised as the most important risk factor for multiresistance. Described resistance mechanisms include hydrolysis by beta-lactamases, alterations in outer membrane proteins and penicillin-binding proteins, and increased activity of efflux pumps. Today, Acinetobacter resistant to carbapenems, aminoglycosides and fluoroquinolones presents a challenge to the clinician. However, sulbactam, tigecycline and colistin represent the current therapeutic approaches, which are associated with satisfactory efficacy. (C) 2008 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:106 / 119
页数:14
相关论文
共 150 条
  • [51] Susceptibility of Acinetobacter strains isolated from deployed US military personnel
    Hawley, Joshua S.
    Murray, Clinton K.
    Griffith, Matthew E.
    McElmeel, M. Leticia
    Fulcher, Letitia C.
    Hospenthal, Duane R.
    Jorgensen, James H.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (01) : 376 - 378
  • [52] Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936)
    Henwood, CJ
    Gatward, T
    Warner, M
    James, D
    Stockdale, MW
    Spence, RP
    Towner, KJ
    Livermore, DM
    Woodford, N
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (03) : 479 - 487
  • [53] Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 β-lactamase:: Defining a unique family of class C enzymes
    Hujer, KM
    Hamza, NS
    Hujer, AM
    Perez, F
    Helfand, MS
    Bethel, CR
    Thomson, JM
    Anderson, VE
    Barlow, M
    Rice, LB
    Tenover, FC
    Bonomo, RA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (07) : 2941 - 2948
  • [54] Influence of relative humidity and suspending menstrua on survival of Acinetobacter spp on dry surfaces
    Jawad, A
    Heritage, J
    Snelling, AM
    GascoyneBinzi, DM
    Hawkey, PM
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (12) : 2881 - 2887
  • [55] Survival of Acinetobacter baumannii on dry surfaces:: Comparison of outbreak and sporadic isolates
    Jawad, A
    Seifert, H
    Snelling, AM
    Heritage, J
    Hawkey, PM
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (07) : 1938 - 1941
  • [56] Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam
    Jellison, TK
    McKinnon, PS
    Rybak, MJ
    [J]. PHARMACOTHERAPY, 2001, 21 (02): : 142 - 148
  • [57] Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 β-lactamase in Korea
    Jeon, BC
    Jeong, SH
    Bae, IK
    Kwon, SB
    Lee, K
    Young, D
    Lee, JH
    Song, JS
    Lee, SH
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (05) : 2241 - 2245
  • [58] Clinical impact and pathogenicity of Acinetobacter
    Joly-Guillou, ML
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2005, 11 (11) : 868 - 873
  • [59] Importation of multidrug-resistant Acinetobacter spp infections with casualties from Iraq
    Jones, Anna
    Morgan, Dilys
    Walsh, Amanda
    Turton, Jane
    Livermore, David
    Pitt, Tyrone
    Green, Andy
    Gill, Martin
    Mortiboy, Deborah
    [J]. LANCET INFECTIOUS DISEASES, 2006, 6 (06) : 317 - 318
  • [60] Doripenem (S-4661), a novel carbapenem:: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations
    Jones, RN
    Huynh, HK
    Biedenbach, DJ
    Fritsche, TR
    Sader, HS
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (01) : 144 - 154